Guangzhou Innogen Pharmaceutical Group Co. Ltd. has announced a significant milestone in the commercialization of its Core Product for the treatment of type 2 diabetes. The company has received regulatory approval for its biologics license application (BLA) in the Macau Special Administrative Region of China. As of September 12, 2025, the first prescription for the product, Efsubaglutide Alfa, has been issued at Centro Médico HB in Macau, marking the official commencement of its commercial sale in the region. The company, however, cautions that successful market penetration is not guaranteed and advises shareholders and potential investors to exercise due care.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.